Abstracts

A FC-ENHANCED NON-NEUTRALIZING ANTIBODY DELAYS SARS-CoV-2–INDUCED DEATH IN MICE

Both neutralizing activity and Fc-mediated effector functions of antibodies are believed to contribute to protection against SARS-CoV-2. However, it is unclear if antibody effector functions alone could protect against SARS-CoV-2 infection. We isolated CV3-13 from a convalescent individual with potent Fc-mediated effector functions. Neutralization capacity of this antibody was measured by both a pseudovirus neutralization…

CDK INHIBITORS IMPACT HIV-1 SUSCEPTIBILITY BY MODULATING IN VIVO IMMUNOLOGIC RESPONSE

Protein kinase inhibitors have been proposed as novel strategies for HIV-1 control, although in vivo evidences from treated patients are limited. Among them, cyclin-dependent kinase inhibitors (CDKi) are orally, well-tolerated drugs currently used for the treatment of metastatic breast cancer (BC), with well-described effects on viral replication and immune cell responses in vitro. Here, using…

EX VIVO ASSAY PREDICTS HIV-1 SUPPRESSION BY bNAbs INFUSED IN A PHASE I CLINICAL TRIAL

Broadly neutralizing antibodies (bNAbs) target conserved regions of the HIV-1 envelope and show potential as complementary immunotherapy to combination anti-retroviral therapies (cART) for HIV-1 treatment. However, infusion of a single bNAb in viremic individuals results in selection for escape variants that are likely part of the individuals viral quasispecies. To better predict the potential for…

ChAdOx1 nCoV-19 VACCINATION IN PWH: IMMUNE RESPONSES TO SARS-CoV-2, VOCs, AND HCoVs

People living with HIV (PWH) may represent a high-risk group for adverse clinical outcomes from SARS-CoV-2. The duration of protection from SARS-CoV-2 and emerging variants of concern (VOC) infection in PWH following vaccination is unclear. Furthermore, the role of pre-existing SARS-CoV-2 immune responses, likely acquired from prior exposure to circulating human coronaviruses (HCoVs), on vaccine-mediated…